DWP
ENTA icon

Daymark Wealth Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Daymark Wealth Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$112K – 402
2023
Q3 		$112K Buy
+10,000
New +$161K 0.01% 371

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Daymark Wealth Partners's ENTA Position: Q4 2023 in Review

Daymark Wealth Partners sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 10,000 shares — an estimated $112K sold.

Daymark Wealth Partners first reported a position in ENTA in Q3 2023 and held it in 1 quarter. The position peaked at $112K in Q3 2023. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Daymark Wealth Partners reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Daymark Wealth Partners sold 10,000 Enanta Pharmaceuticals shares in Q4 2023, an estimated $112K.
  • Daymark Wealth Partners first reported a position in Enanta Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Daymark Wealth Partners's Enanta Pharmaceuticals position peaked at $112K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Daymark Wealth Partners's 13F filing for Q4 2023, filed 9 Jan 2024.